Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSC | P53634 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20680879 | 0.81 | EGFR (0.55) | EGFRERBB2BRPF1MAPK1CTSB | |
| SCHEMBL20680878 | 0.79 | EGFR (0.51) | EGFRERBB2GAABRPF1MAPK1 | |
| SCHEMBL25348763 | 0.79 | SMN1; SMN2 (0.40) | GAAMAPK1ALDH1A1 | |
| SCHEMBL20689782 | 0.79 | EGFR (0.52) | EGFRERBB2GAABRPF1MAPK1 | |
| SCHEMBL20681362 | 0.78 | EGFR (0.54) | EGFRERBB2BRPF1MAPK1CTSB | |
| SCHEMBL25976434 | 0.78 | EGFR (0.50) | EGFRERBB2BRPF1MAPK1CTSB | |
| SCHEMBL23248562 | 0.77 | EGFR (0.49) | EGFRERBB2GAABRPF1MAPK1 | |
| SCHEMBL23983218 | 0.77 | EGFR (0.53) | EGFRERBB2BRPF1MAPK1CTSB | |
| SCHEMBL25349060 | 0.76 | MAPT (0.48) | GAAALDH1A1 | |
| SCHEMBL19027874 | 0.71 | EGFR (0.52) | EGFRERBB2CTSBCTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322753-A1 | HETEROARYL DERIVATIVE, METHOD FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | VORONOI INC. (KR) | 2023-10-12 | — | — | US | disclosed |
| EP-4215529-A1 | HETEROARYL DERIVATIVE, METHOD FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Voronoibio Inc. (KR) | 2023-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322753-A1 | HETEROARYL DERIVATIVE, METHOD FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | ERBB4, ERBB2, ERBB3 | EGFR 4/4885ERBB2 2/4885GAA 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.